Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

Core Points - Reneo Pharmaceuticals and OnKure, Inc. are merging, with the combined company to be named OnKure Therapeutics, Inc. and trading under the ticker "OKUR" on Nasdaq [2] - The merger is expected to close on or around October 4, 2024, and will focus on advancing OnKure's pipeline targeting oncogenic mutations in PI3Kα [2] - Reneo will implement a 1-for-10 reverse stock split prior to the merger, affecting the common stock of the combined company [3][4] Company Overview - Reneo Pharmaceuticals specializes in therapies for rare genetic mitochondrial diseases [9] - OnKure, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines targeting cancer drivers, with its lead program OKI-219 currently in Phase 1 clinical trials [8]